Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.

Leavitt AD, Konkle BA, Stine KC, Visweshwar N, Harrington TJ, Giermasz A, Arkin S, Fang A, Plonski F, Yver A, Ganne F, Agathon D, Resa MLA, Tseng LJ, Di Russo G, Cockroft BM, Cao L, Rupon J

Open source

DOI: 10.1182/blood.2022018971
Published: 2024 Feb 29
Container: Blood
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood.2022018971,
  title = {Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.},
  author = {Leavitt AD and Konkle BA and Stine KC and Visweshwar N and Harrington TJ and Giermasz A and Arkin S and Fang A and Plonski F and Yver A and Ganne F and Agathon D and Resa MLA and Tseng LJ and Di Russo G and Cockroft BM and Cao L and Rupon J},
  year = {2024},
  journal = {Blood},
  doi = {10.1182/blood.2022018971},
  url = {https://doi.org/10.1182/blood.2022018971}
}

RIS

TY  - JOUR
TI  - Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.
AU  - Leavitt AD
AU  - Konkle BA
AU  - Stine KC
AU  - Visweshwar N
AU  - Harrington TJ
AU  - Giermasz A
AU  - Arkin S
AU  - Fang A
AU  - Plonski F
AU  - Yver A
AU  - Ganne F
AU  - Agathon D
AU  - Resa MLA
AU  - Tseng LJ
AU  - Di Russo G
AU  - Cockroft BM
AU  - Cao L
AU  - Rupon J
PY  - 2024
JO  - Blood
DO  - 10.1182/blood.2022018971
UR  - https://doi.org/10.1182/blood.2022018971
ER  -

APA

AD, L., BA, K., KC, S., N, V., TJ, H., A, G., S, A., A, F., F, P., A, Y., F, G., D, A., MLA, R., LJ, T., G, D. R., BM, C., L, C., & J, R. (2024). Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.. Blood. https://doi.org/10.1182/blood.2022018971

Source records

pubmed · retrieved 2026-09-26T20:30:18.034Z